SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Sanofi SNYNF OTC

Other OTC • Healthcare • Drug Manufacturers - General • FR • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Sanofi (SNYNF) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $94.31. It has a SharesGrow Score of 68/100, indicating a above average investment profile with 5 out of 7 criteria passed.

Financials: revenue is $43.6B, -1.3%/yr average growth. Net income is $7.8B, growing at +2.6%/yr. Net profit margin is 17.9% (healthy). Gross margin is 70.1% (+0.3 pp trend).

Balance sheet: total debt is $20.3B against $71.3B equity (Debt-to-Equity (D/E) ratio 0.28, conservative). Current ratio is 1.09 (adequate). Debt-to-assets is 16%. Total assets: $126.8B.

Analyst outlook: 11 / 23 analysts rate SNYNF as buy (48%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 85/100 (Pass), Growth 30/100 (Fail), Past 100/100 (Pass), Health 83/100 (Pass), Moat 86/100 (Pass), Future 20/100 (Fail), Income 70/100 (Pass).

SNYNF SharesGrow Score Overview

68/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 85/100

Valuation — P/E, PEG, Forward PEG

GROWTH 30/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 86/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 70/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SNYNF

SNYNF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

SNYNF: -1.3%/yr revenue is, +2.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

SNYNF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet SNYNF: Debt-to-Equity (D/E) ratio 0.28 (conservative), Current ratio is 1.09 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

SNYNF: Gross margin is 70.1% (+0.3 pp trend), $113B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 86/100. ≥ 70 = Pass.

View details →

Analyst outlook: 11 / 23 analysts rate SNYNF as buy (48%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

SNYNF: Net profit margin is 17.9%. healthy (≥15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range85.74-113.69

Volume166

Avg Volume (30D)28.92K

Market Cap$113.46B

Beta (1Y)0.32

Dividend Yield$4.4100

Share Statistics

EPS (TTM)6.40

Shares Outstanding$1.22B

IPO Date2008-04-09

Employees82,878

CEOOlivier Charmeil

Financial Highlights & Ratios

Revenue (TTM)$43.61B

Gross Profit$30.57B

EBITDA$6.74B

Net Income$7.81B

Operating Income$14.25B

Total Cash$7.65B

Total Debt$20.33B

Net Debt$12.94B

Total Assets$126.76B

Price / Earnings (P/E)14.7

Price / Sales (P/S)2.6

Analyst Forecast

Rating ConsensusBuy

Analysts Covering23

Buy 48% Hold 39% Sell 13%

Company Info

CountryFR

ExchangeOther OTC

CurrencyUSD

ISINFR0000120578

Price Chart

SNYNF

Sanofi ↗ · Other OTC

Healthcare • Drug Manufacturers - General

85.74 52WK RANGE 113.69

People Also View

Johnson & Johnson

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Gilead Sciences, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message